je.st
news
Tag: percent
Apple claims more than 90 percent of genuine Apple chargers sold on Amazon are fake
2016-10-20 13:30:44| Extremetech
Apple has filed suit against a company it accuses of falsely representing that its products are genuine Apple cables and adapters when they absolutely aren't. Up to 90% of the "genuine" Apple cables and adapters sold on Amazon are estimated to be fake.
Greenland ice is melting 7 percent faster than previously thought
2016-10-14 12:00:00| LifeSciencesWorld
[NEWS] COLUMBUS, Ohio—The same hotspot in Earth's mantle that feeds Iceland's active volcanoes has been playing a trick on the scientists who are trying to measure how much ice is melting on nearby Greenland. According to a new study in the journal Science Advances, the hotspot softened the mantle rock beneath Greenland in a way that ultimately distorted their calculations for ice loss in the Greenland ice sheet. This caused them to underestimate the mel…
Tags: thought
previously
percent
ice
iOS 10 Adoption Tops 50 Percent
2016-10-11 19:02:23| PC Magazine Software Product Guide
The next-gen OS was installed on 54 percent of active iDevices as of Oct. 7, according to Apple.
Tags: percent
adoption
tops
ios
iOS 10 Adoption Tops 50 Percent
2016-10-11 19:02:22| PC Magazine Cell Phones Product Guide
The next-gen OS was installed on 54 percent of active iDevices as of Oct. 7, according to Apple.
Tags: percent
adoption
tops
ios
New KEYTRUDA (pembrolizumab) Data in Advanced Urothelial Cancer Demonstrate Overall Response Rate of 24 Percent in Cisplatin-Ineligible Patients
2016-10-08 08:15:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Results from Interim Analysis of Phase 2 KEYNOTE-052 Study to be Presented at ESMO 2016 Congress and Highlighted in ESMO Press Program First Presentation of Data Investigating KEYTRUDA in the Front Line Treatment of Bladder Cancer KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced positive findings from the phase 2 KEYNOTE-052 study investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in previously untreated patients with unresectable (inoperable) or metastatic urothelial cancer who are ineligible for cisplatin-based therapy. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
advanced
rate
response
Sites : [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] next »